Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: Sample variability and data classification

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 9, 2010, Pages 1319-1326

  Camaggi, Carlo M ^a   Zavatto, Elena ^a   Gramantieri, Laura ^a   Camaggi, Valeria ^a   Strocchi, Elena ^a   Righini, Roberto ^a   Merina, Luca ^a   Chieco, Pasquale ^a   Bolondi, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

cirrhosis; hepatocarcinoma; matrix assisted laser desorption ionization time of flight (MALDI TOF); proteomic signature; Random Forest; variability

Indexed keywords

PEPTIDE; SERUM ALBUMIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER INVASION; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MACHINE LEARNING; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEOMICS; QUALITY CONTROL; RANDOM FOREST; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ARTIFICIAL INTELLIGENCE; BLOOD VESSELS; CARCINOMA, HEPATOCELLULAR; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PEPTIDES; PROTEIN BINDING; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77957308115     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.248     Document Type: Article

References (18)

1. Anderson NL, Anderson NG. The human plasma proteome. Proteomics 2002;11:845-67.
2. Liotta, LA, Petricoin E. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006;116:26-30. (Pubitemid 43121786)
3. Chan DW, Semmes OJ, Petricoin EF, Liotta LA, van der Merwe D, Diamandis EP. National Academy of Clinical Biochemistry Guidelines: the use of MALDI-TOF mass spectrometry profiling to diagnose cancer. NACB: Practice Guidelines and Recommendations for the use of tumor markers in the clinic. MALDI-TOF Mass Spectrometry Profiling (Section 4B). 2005.
4. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1): S5-16. (Pubitemid 39423365)
5. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004;126:1005-14. (Pubitemid 38451172)
6. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patients survival. Hepatology 1992;16:132-7.
7. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007;43:979-92. (Pubitemid 46483030)
8. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1): S108-12. (Pubitemid 39423377)
9. Bruix J, Sherman M. Practice guidelines committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
10. Kragh-Hansen U, Chuang VT, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002;25:695-704. (Pubitemid 40036701)
11. Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 1998;5:827-35. (Pubitemid 28402087)
12. Hilario M, Kalousis A. Approaches to dimensionality reduction in proteomic biomarker studies. Brief Bioinform 2008;9:102-18. (Pubitemid 351516997)
13. Cohen SL, Chait BT. Influence of matrix solution conditions on the MALDI-MS analysis of peptides and proteins. Anal Chem 1996;68:31-7. (Pubitemid 26199301)
14. Breiman L. Random forests. Machine Learning 2001;45:5-32. (Pubitemid 32933532)
15. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002;277:35035-43.
16. Izmiliarn G. Application of the Random Forest classification algorithm to a SELDI-TOF proteomic study in the setting of a cancer prevention trial. Ann N Y Acad Sci 2004;1020:154-74.
17. Diaz-Uriarte R, Alvarez de Andres S. Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006;7:3-15. (Pubitemid 43085344)
18. McLachlan GJ, Do KA, Ambroise C, editors. Analyzing microarray gene expression data. Hoboken, New Jersey: John Wiley & Sons Inc, 2004.